SiO Medical Products (SMP), a U.S.-based designer, developer, manufacturer, and supplier of pharmaceutical packaging, labware, and consumables products, and Sanaria, a U.S.-based developer, manufacturer, and supplier of vaccines, announced the signing of an agreement for the development, manufacture, and supply of cryogenic vials for Sanaria's malaria vaccine, Sanaria PfSPZ Vaccine.
According to the World Health Organization, malaria caused an estimated 429,000 deaths and 214 million clinical cases in 2015.
"Our goal is the development, licensure and fielding of a vaccine to prevent malaria. We are excited to partner with SMP, because we share the same passion and determination. We are confident that SMP's agility, speed, and expertise will help us achieve our goal," said Stephen L. Hoffman, CEO of Sanaria.
"SMP is humbled to have been selected by Sanaria as a partner in its fight against malaria. The development of Sanaria's highly effective vaccine promises hope for millions affected by this disease. With such a vital vaccine in its final clinical development stages, SMP has dedicated its world-class team to develop the ideal container to meet Sanaria's needs and timelines. We are confident that Sanaria's vaccine preserved in SMP's cryogenic vials will provide the optimal solution for delivering the vaccine to those in need," said Brian Maurer, Sr. Vice President of SMP.
SiO Medical Products is a U.S. based, privately-held company founded in 2011. SMP develops and manufactures precision-molded containers and products composed of engineered polymers, such as cyclic olefin polymers (COP). SMP has in-house material science expertise of a broad range of proprietary coatings or treatments to enhance the properties of the underlying polymeric surfaces.